ArticleKidney international reports2025
The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Principles for Optimal Drug Selection in IgA Nephropathy-Time for Integrating Pathogenesis and Clinical Markers to Guide Therapy.Nephrology (Carlton, Vic.) · 2026Review
- Precision targeting of gut-kidney axis: mucosal immunomodulation in IgA nephropathy-a perspective.Frontiers in medicine · 2026Article
- Autoimmunity in IgA nephropathy.Frontiers in immunology · 2026Review
- Glomerular Galactose-Deficient IgA1 Deposition in 192 Autopsy Cases in Japan.Nephrology (Carlton, Vic.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In IgA nephropathy (IgAN), the mechanism of IgA-containing immune complexes deposition in the glomerular mesangium had been unclear. We recently reported the presence of IgA antibodies with specificity for mesangial cells (antimesangium IgA antibodies) in sera from patients with IgAN, and identified β2-spectrin (SPTBN1) and CBX3 as target antigens. However, the role of antimesangium IgA antibodies in human IgAN is unclear. Methods: We measured serum anti-SPTBN1 and anti-CBX3 IgA levels in patients with IgAN ( Results: Overall, 30 and 3 patients with IgAN and DC, respectively, had detectable anti-SPTBN1 IgA antibodies (sensitivity, 25%; specificity, 94%); whereas 48 and 3 patients with IgAN and DC, respectively, had detectable anti-CBX3 IgA antibodies (sensitivity, 40%; specificity, 94%). In total, 62 patients (52%) with IgAN had detectable anti-SPTBN1 and/or anti-CBX3 IgA antibodies. The expression of SPTBN1 and CBX3 on the surface of human mesangial cells was confirmed by immunofluorescence (IF) microscopy. Serum anti-SPTBN1 and anti-CBX3 IgA antibodies from patients with IgAN were recognized by an antigalactose-deficient IgA1 antibody (KM55) by Western blotting. Conclusion: We show that anti-SPTBN1 and anti-CBX3 IgA antibodies are detected with high specificity in patients with IgAN from Japan and the UK, and are enriched for IgA1 with poorly galactosylated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.